A Clinical Validation of Safety and Effectiveness of Pain Relief and Joint Mobility Tablet

Abstract: Introduction: Millions of people worldwide are dealing with joint discomfort and issues with mobility, which are mostly caused by diseases like rheumatoid arthritis and osteoarthritis. These illnesses not only hurt physically but also seriously limit mobility, which diminishes activity levels and impairs quality of life. Materials and Methods: An open-label, single-arm, safety study was conducted on 32 individuals. One tablet of Pain Relief and Joint Mobility twice daily after a meal for 30 days was given. The research objectives were to evaluate changes in compliance, clinical, vital parameter assessment, and tolerability of the investigational product from baseline to the end of the study. Changes in complete blood count (CBC), liver function test(LFT), and renal function test (RFT)parameters on screening and day 30. Results: The analysis of the vital sign parameters revealed a statistically significant decrease in diastolic blood pressure (p=0.0075) and body temperature (p=0.0133) from the screening to day 30 time points. Hematological and biochemical investigations demonstrated no clinically significant changes from baseline to endpoint, indicating the safety of the intervention. After a 30-day treatment regimen, significant reductions were observed across all Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales: a 32.42%, 34.12%, and 34.76% decrease in pain, stiffness, and physical function scores respectively, indicating substantial alleviation of pain, improvement in stiffness, and enhanced physical function. Conclusion: The study indicates that the Pain Relief and Joint Mobility Tablet is found to be safe and effective in managing joint pain and mobility issues, proving beneficial for patients ranging from those newly diagnosed to those with chronic conditions.